Ironwood Pharmaceuticals

Cardio-vascularGastro-intestinals

Ironwood Pharmaceuticals

Ironwood's (Nasdaq: IRWD) lead drug Linzess (linaclotide) is approved in the USA for the treatment of adults with irritable bowel syndrome with constipation (IBS-C).

Ironwood's (Nasdaq: IRWD) lead drug Linzess (linaclotide) is approved in the USA for the treatment of adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC).

It began with Ironwood's research on the intestinal enzyme guanylate cyclase-C (GC-C), found mainly on the surface of the intestine and is thought to be a potential target for a variety of gastrointestinal diseases.

It is exploring the use of linaclotide in other indications, as well as working on GC-C research and looking at other areas such as allergic conditions and cardiovascular disease, as well as CNS disorders.


Latest Articles

Who's Who

Company Spotlight

ImmunoGen

ImmunoGen

Back to top